ArticleJACC. Case reports2025
Physiological Scaffold Remodeling in the Coronary Artery After 30 Months of Bioadaptor Implantation.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DynamX Bioadaptor as an Emerging and Promising Innovation in Interventional Cardiology.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DynamX Bioadaptor (Elixir Medical Corporation) is a novel coronary artery scaffold consisting of 3 helical strands connected by a bioabsorbable polymer. After 6 months, the polymer dissolves, restoring the physiological motion of the coronary artery as the interconnected (caged) structure of the scaffold disengages. Here we report the cases of 2 patients treated with the Bioadaptor who underwent intravascular imaging at the time of the index procedure and during follow-up periods of 30 and 36 months, respectively. The cross-sectional images of the scaffold were analyzed and compared with those obtained during the index procedure. At follow-up, the mean cross-sectional area of the scaffold was increased significantly in both cases, regardless of the degree of intimal hyperplasia. Such unique properties of the Bioadaptor make it a promising alternative to contemporary drug-eluting stents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.